Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 4 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Tristan Manalac, 04 Sep 2020
Anticoagulation therapy may be of value to patients with new-onset atrial fibrillation (AF) associated with sepsis, easing the risk of all-cause mortality and ischaemic stroke without increasing the likelihood of major bleeding, reports a study presented at the Digital 2020 Congress of the European Society of Cardiology (ESC).

Good midterm outcomes seen in congenital heart disease-related PAH

2 days ago

Patients with congenital heart disease-associated pulmonary artery hypertension (CHD-PAH) have favourable midterm outcomes, a new study reports.

Researchers established a multi-centre prospective registry called the TACHYON*, which included nine paediatric cardiology centres. The present study included 87 CHD-PAH patients (mean age, 37.4±18.2 years), from whom relevant clinical and laboratory data were collected every 3 months for the first year, and once per year thereafter.

Over a mean follow-up duration of 23.9 months, nine patients needed to be admitted more than once for cardiopulmonary reasons, and five died. The 2-year Kaplan-Meier survival rate was 93.2 percent, while the hospitalization-free survival rate over the same time span was 91.8 percent.

The researchers then assessed the value of three noninvasive parametersfunctional class, the 6-minute walk distance (6MWD), and N-terminal pro-brain natriuretic peptide (NT-pro BNP)/BNPin predicting adverse outcomes during follow-up.

They found that survival and hospitalization-free survival rates were not statistically different between patients with any number of low-risk findings in any of the three parameters. However, the total number of high-risk findings held significant predictive value. Those with zero high-risk noninvasive findings had significantly better 2-year total (p=0.002) and cardiopulmonary hospitalization-free (p=0.005) survival rates.

Notably, adherence of physicians to the European Society of Cardiology (ESC) guidelines for CHD-PAH follow-up was low. The registration rate of cardiopulmonary exercise testing (CPET) was very low, at 3 percent, and only 14 percent of patients were made to undergo repeat cardiac catheterization.

*Taiwan congenital heart disease associated with pulmonary arterial hypertension

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 4 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Tristan Manalac, 04 Sep 2020
Anticoagulation therapy may be of value to patients with new-onset atrial fibrillation (AF) associated with sepsis, easing the risk of all-cause mortality and ischaemic stroke without increasing the likelihood of major bleeding, reports a study presented at the Digital 2020 Congress of the European Society of Cardiology (ESC).